Arecor is leveraging its unique formulation platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides.

More information can be found under PRODUCTS.


By 2018 the global therapeutic peptide market is expected to reach sales of >$25 billions. However, improving stability and enabling innovative and convenient routes of administration remains a significant challenge due to a number of stability-related challenges, particularly:

  • Poor solubility
  • Gel formation
  • Formation of fibrils or particles
  • Hydrolytic cleavage
  • Formation of charge variants

Arecor has an excellent track record in improving physical stability, such as preventing gel and particle formation, in addition to unique formulations’ platforms to address hydrolytic degradation and other aspects of chemical stability of therapeutic peptides.


If you are interested in learning more please contact us.